Shots: Lundbeck acquires Alder BioPharmaceuticals in the all-cash transaction making a total deal value $1.95B. Alder to receive $18/share as upfront, non-tradeable CVR of $2/share on EMA’s approval of Eptinezumab […]readmore
Tags : Acquire
Shots: Aytu acquires Innovus in cash & stock transaction making a total deal value up to $24M. Innovus to receive up to $8M shares in Aytu’s common stock as upfront […]readmore
Shots: Sanofi signs a business transfer agreement with Zentiva to sell its manufacturing facility in Ankleshwar, India. In H1’19, Zentiva enhanced its network with the acquisition of Solacium in Romania […]readmore
Shots: GSK signs an agreement with Avalon Ventures to acquire Sitari Pharmaceutical with its all intellectual property rights and obtain transglutaminase 2 small molecule program for celiac disease In Apr’2013, […]readmore
Shots: Baxter acquires Cheetah Medical for up to $230M including $190M as up front with $40M as clinical & development milestones. The acquisition is expected to close in Q4’19 The […]readmore
Shots: OncoCyte acquires 25% stake in Razor and has an option to acquire its remaining shares. Razor to receive $10M for initial acquiring of 25% stock in its preferred share […]readmore
Shots: Vertex acquires Semma Therapeutics, in all cash transaction making a total deal value $950M and Semma will operate as a subsidiary of Vertex. The transaction is expected to be […]readmore
Shots: Everyday Health acquires BabyCenter combining its What to Expect digital pregnancy and parenting platform, with the focus of supporting parents through the journey of pregnancy and early parenting plus […]readmore
Shots: Modi to receive $250M up front including $175M in cash & $75M in Zogenix’s common stock, ~$150M as regulatory milestone comprising $100M on the US FDA’s approval and $50M […]readmore
Shots: Amgen to acquire Otezla for $13.4B in cash and will receive its related intellectual property including patents primarily covering apremilast with all assets and liabilities related to Otezla along […]readmore